Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy-Reference-Cited by-同舟云学术

Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy

Published:2015-12 Issue: Volume:73 Page:64-69
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Kim Ji-Won^ORCID,Min Chang-Ki,Mun Yeung-Chul,Park Yong,Kim Byung Soo,Nam Seung-Hyun,Koh Youngil,Kwon Ji-Hyun,Choe Pyoeng Gyun,Park Wan Beom,Kim Inho

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference21 articles.

1. Proteasome inhibition as a novel therapeutic target in human cancer;Rajkumar;J. Clin. Oncol.,2005

2. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N. Engl. J. Med.,2008

3. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial;Harousseau;J. Clin. Oncol.,2010

4. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients;Tong;Am. J. Hematol.,2007

5. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study;Chanan-Khan;J. Clin. Oncol.,2008

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients;Cancer Medicine;2022-09-20

2. Cytomegalovirus and Other Herpesviruses;Infectious Complications in Biologic and Targeted Therapies;2022

3. Neurophysiological Mechanisms Related to Pain Management in Bone Tumors;Current Neuropharmacology;2021-03-15

4. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients;BMC Infectious Diseases;2021-01-26

5. Treatment of Secondary Immunodeficiencies;Reference Module in Biomedical Sciences;2021